5-[(Z)-5-Chloro-2-oxoindolin-3-ylidene]-3-{(E)-[(4-hydroxyphenyl)imino]methyl}-2-thioxothiazolidin-4-one
Abstract
:1. Introduction
2. Results and Discussion
3. Materials and Methods
3.1. General Information
General Procedure for Synthesis and Characterization of 4
4. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References and Note
- Lockman, J.W.; Reeder, M.D.; Robinson, R.; Ormonde, P.A.; Cimbora, D.M.; Williams, B.L.; Willardsen, J.A. Oxindole derivatives as inhibitors of TAK1 kinase. Bioorg. Med. Chem. Lett. 2011, 21, 1724–1727. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.M.; Di, H.; Hanson, P.J.; Li, H.; Guo, H.; Ye, X.; Hemida, M.G.; Wang, L.; Tong, Y.; Qiu, Y.; et al. Antiviral Activity of an Isatin Derivative via Induction of PERK-Nrf2-Mediated Suppression of Cap-Independent Translation. ACS Chem. Biol. 2014, 9, 1015–1024. [Google Scholar] [CrossRef] [PubMed]
- Asati, V.; Bharti, S.K.; Budhwani, A.K. 3D-QSAR and virtual screening studies of thiazolidine-2,4-dione analogs: Validation of experimental inhibitory potencies towards PIM-1 kinase. J. Mol. Struct. 2017, 1133, 278–293. [Google Scholar] [CrossRef]
- Hueso-Falcón, I.; Amesty, Á.; Anaissi-Afonso, L.; Lorenzo-Castrillejo, I.; Machín, F.; Estévez-Braun, A. Synthesis and biological evaluation of naphthoquinone-coumarin conjugates as topoisomerase II inhibitors. Bioorg. Med. Chem. Lett. 2017, 27, 484–489. [Google Scholar] [CrossRef] [PubMed]
- Kaminskyy, D.; Kryshchyshyn, A.; Lesyk, R. 5-Ene-4-thiazolidinones–An efficient tool in medicinal chemistry. Eur. J. Med. Chem. 2017, 140, 542–594. [Google Scholar] [CrossRef] [PubMed]
- Shu, C.; Ge, H.; Song, M.; Chen, J.H.; Zhou, H.; Qi, Q.; Wang, F.; Ma, X.; Yang, X.; Zhang, G.; et al. Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes. ACS Med. Chem. Lett. 2014, 5, 921–926. [Google Scholar] [CrossRef] [PubMed]
- Sun, H.; Tawa, G.; Wallqvist, A. Classification of scaffold-hopping approaches. Drug Discov. Today 2012, 17, 310–324. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Carlson, E.E.; May, J.F.; Kiessling, L.L. Chemical Probes of UDP-Galactopyranose Mutase. Chem. Biol. 2006, 13, 825–837. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Furdas, S.D.; Shekfeh, S.; Kannan, S.; Sippl, W.; Jung, M. Rhodanine carboxylic acids as novel inhibitors of histone acetyltransferases. MedChemComm 2012, 3, 305–311. [Google Scholar] [CrossRef]
- Baell, J.B. Observations on screening-based research and some concerning trends in the literature. Future Med. Chem. 2010, 2, 1529–1546. [Google Scholar] [CrossRef] [PubMed]
- Glaser, J.; Holzgrabe, U. Focus on PAINS: False friends in the quest for selective anti-protozoal lead structures from Nature? Med. Chem. Comm. 2016, 7, 214–223. [Google Scholar] [CrossRef]
- Kaminskyy, D.; Kryshchyshyn, A.; Lesyk, R. Recent developments with rhodanine as a scaffold for drug discovery. Expert Opin. Drug Discov. 2017, 12, 1233–1252. [Google Scholar] [CrossRef] [PubMed]
- Gilberg, E.; Gütschow, M.; Bajorath, J. X-ray Structures of Target–Ligand Complexes Containing Compounds with Assay Interference Potential. J. Med. Chem. 2018, 61, 1276–1284. [Google Scholar] [CrossRef] [PubMed]
- The supplementary crystallographic data have been deposited at the Cambridge Crystallographic Data Centre (CCDC), 12 Union ROAD, Cambridge CB2 1EZ (UK), Tel.: (þ44) 1223/336 408, fax: (þ44) 1223/336 033, E-mail: [email protected], World Wide Web: http://www.ccdc.cam.ac.uk (deposition No. CCDC 1871619).
- Sheldrick, G.M. SHELXT—Integrated Space-Group and Crystal-Structure Determination. Acta Cryst. A 2015, 71, 3–8. [Google Scholar] [CrossRef] [PubMed]
- Sheldrick, G. A short history of SHELX. Acta Crystallogr. Sect. A 2008, 64, 112–122. [Google Scholar] [CrossRef] [PubMed]
- Farrugia, L. WinGX and ORTEP for Windows: An update. J. Appl. Crystallogr. 2012, 45, 849–854. [Google Scholar] [CrossRef]
- Mercury—Crystal Structure Visualisation, Exploration and Analysis Made Easy. Available online: https://www.ccdc.cam.ac.uk/solutions/csd-system/Components/Mercury/ (accessed on 11 January 2019).
Empirical formula | C18H10ClN3O3S2 |
Formula weight | 415.87 |
Crystal size (mm) | 0.600 × 0.150 × 0.120 |
Temperature (K) | 150 |
Crystal system. space group | Triclinic. P-1 |
Unit cell dimensions | |
a (Å) | 5.1368(9) |
b (Å) | 13.808(2) |
c (Å) | 15.155(2) |
α (°) | 77.532(5) |
β (°) | 89.435(6) |
γ (°) | 84.146(6) |
Wavelength (Å) | 0.71073 |
Volume (Å3) | 1044.0(3) |
Z. calculated density (g/cm3) | 2, 1.571 |
θ range for data collection | 3.038° to 27.484° |
Limiting indices | −6 ≤ h ≤ 6, −17 ≤ k ≤ 17, −19 ≤ l ≤ 15 |
Reflections collected/total/unique | 21366/4584 [R(int)a = 0.1135] |
Refinement method | Full-matrix least-squares on F2 |
Data/restraints/parameters | 4584/0/283 |
Goodness of fit on F2 | 1.057 |
Final R indices | |
R1 | 0.0556 |
wR2 | 0.1257 |
R indices (all data) | |
R1 | 0.0841 |
wR2 | 0.1387 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Safer, A.; Khaldoun, K.; Saidi-Besbes, S. 5-[(Z)-5-Chloro-2-oxoindolin-3-ylidene]-3-{(E)-[(4-hydroxyphenyl)imino]methyl}-2-thioxothiazolidin-4-one. Molbank 2019, 2019, M1059. https://doi.org/10.3390/M1059
Safer A, Khaldoun K, Saidi-Besbes S. 5-[(Z)-5-Chloro-2-oxoindolin-3-ylidene]-3-{(E)-[(4-hydroxyphenyl)imino]methyl}-2-thioxothiazolidin-4-one. Molbank. 2019; 2019(2):M1059. https://doi.org/10.3390/M1059
Chicago/Turabian StyleSafer, Abdelmounaim, Khadidja Khaldoun, and Salima Saidi-Besbes. 2019. "5-[(Z)-5-Chloro-2-oxoindolin-3-ylidene]-3-{(E)-[(4-hydroxyphenyl)imino]methyl}-2-thioxothiazolidin-4-one" Molbank 2019, no. 2: M1059. https://doi.org/10.3390/M1059
APA StyleSafer, A., Khaldoun, K., & Saidi-Besbes, S. (2019). 5-[(Z)-5-Chloro-2-oxoindolin-3-ylidene]-3-{(E)-[(4-hydroxyphenyl)imino]methyl}-2-thioxothiazolidin-4-one. Molbank, 2019(2), M1059. https://doi.org/10.3390/M1059